Microbiome Immunotherapy Toxicity and Response Evaluation

NCT04107168 · clinicaltrials.gov ↗

UNKNOWN

Status

1800

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Renal Cancer
Lung Cancer

Interventions

DRUG: Nivolumab
DRUG: Pembrolizumab
DRUG: Ipilimumab
DRUG: Durvalumab
DRUG: Tremelimumab
DRUG: Atezolizumab
DRUG: Bevacizumab

Sponsor

CCTU- Cancer Theme

Collaborators

[object Object]